

ion of:

Markland and Ladner

Serial No.:

08/676,125

Filed:

September 25, 1996

Entitled:

Kallikrein-Inhibiting "Kunitz

Domain" Proteins and Analogues Thereof

Attorney Docket No.: DYX-006.2P US(Markland-1B)

Asst. Commissioner for Patents Washington, D.C. 20231

AMENDMENT UNDER 37 CFR §1.115

Sir:

In response to the Office Action dated June 17, 1997 (paper no. 7), Applicants request amendment and reconsideration of the above-captioned application. This paper is filed concurrently with a request under 37 CFR §1.136(a) for an extension of three months, with the appropriate fee under 37 CFR §1.17(c), making the new deadline for response December 17, 1997.

Please amend the above-captioned application as follows:

IN THE SPECIFICATION

On page 2, line 16, correct "chymotrypin-homologous" to read: --chymotrypsinhomologous--.

On page 2, line 28, insert --the-- before "USA".

On page 5, line 13, change "comprise" to read: --comprises--.

On page 5, line 14, change "number" to read: --numbered--.

On page 6, line 10, correct "specified" to read: --specified--.

On page 6, line 29, correct "purposed" to read: --purposes--.

On page 7, line 1, change "Disulfides" to read: --Disulfide--.

Art Unit: 1805

Examiner: N. Degen